CIM
BCRX icon

Contravisory Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Contravisory Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$316K Buy
+37,957
New +$357K 0.06% 179

Other funds holding BCRX

WCM
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
MBI
May Barnhard Investments Bethesda, Maryland $243M AUM 13.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
RF
RHS Financial San Francisco, California $296M AUM 17.24% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Contravisory Investment Management's BCRX Position: Q3 2026 in Review

Contravisory Investment Management opened a new position in BioCryst Pharmaceuticals (BCRX) in Q3 2026: 37,957 shares worth $316K. The stake represents 0.06% of the portfolio and ranks #179 among its holdings.

11 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • Contravisory Investment Management held 37,957 shares of BioCryst Pharmaceuticals worth $316K as of Q3 2026.
  • BioCryst Pharmaceuticals was a new Contravisory Investment Management position in Q3 2026.
  • BioCryst Pharmaceuticals made up 0.06% of Contravisory Investment Management's portfolio in Q3 2026, its #179 holding.
  • 11 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on Contravisory Investment Management's 13F filing for Q3 2026, filed 13 Oct 2026.